Treatment After Palbociclib-containing Regimens
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT04517318
- Lead Sponsor
- Fudan University
- Brief Summary
To evaluate the prescription patterns and treatment outcomes of subsequent therapies after progression on palbociclib in the real world.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
- woman, age > 18 years old
- Diagnosed with HR+/HER2- Metastatic Breast Cancer
- Patients received at least one-cycle next-line treatment after progression on combined palbociclib and endocrine therapy
- Complete medical history was available
Read More
Exclusion Criteria
- Medical history was incomplete
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS 6 weeks Progression free survival
Adverse events 6 weeks Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, Shanghai, China